Cooper Companies, Inc.
COONasdaqOphthalmic GoodsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 16/3040% below fair value
$60.33−0.42 (-0.69%)
Close on Nov 19, 2026Market cap $11.47BP/E 20.6Yield –
Cooper Companies CooperVision Sponsored Studies Started by Year
Periods
Cooper Companies CooperVision Sponsored Studies Started: 6 in FY2026, down 14.3% from a year earlier. That is the lowest of the 10 years on record here.
Latest, FY2026
6
Period ended Oct 31, 2026 (CY2026)
Change on a year earlier
-14.3%
7 in FY2025
History
10 years
Since FY2017
Sources
1
U.S. National Library of Medicine — ClinicalTrials.gov Registry
Where the FY2026 figure comes from
Source: U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Cooper Companies CooperVision Sponsored Studies Started, annual FY2017–FY2026 [Data set]. Compiled from Cooper Companies SEC filings and investor materials. https://stockdatahq.com/stocks/coo/kpis/ct-cvi-studies-started
See every metric in the Cooper Companies KPI table. Data updated Nov 18, 2026.
See a number that looks wrong?